BAM
FLGT icon

Brave Asset Management’s Fulgent Genetics FLGT Stock Holding History

Brave Asset Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,200
Closed -$200K – 156
2022
Q1 		$200K Buy
+3,200
New +$211K 0.07% 139
2021
Q3 		– Sell
-2,500
Closed -$231K – 155
2021
Q2 		$231K Buy
+2,500
New +$200K 0.07% 127

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brave Asset Management's FLGT Position: Q2 2022 in Review

Brave Asset Management sold out of Fulgent Genetics (FLGT) in Q2 2022, closing a stake of 3,200 shares — an estimated $200K sold.

Brave Asset Management first reported a position in FLGT in Q2 2021 and held it in 2 quarters. The position peaked at $231K in Q2 2021. 262 funds tracked by Wall St. Rank hold FLGT as of Q2 2022.

  • Brave Asset Management reported no remaining Fulgent Genetics position as of Q2 2022 after selling out during the quarter.
  • Brave Asset Management sold 3,200 Fulgent Genetics shares in Q2 2022, an estimated $200K.
  • Brave Asset Management first reported a position in Fulgent Genetics in Q2 2021 and held it in 2 quarters.
  • Brave Asset Management's Fulgent Genetics position peaked at $231K in Q2 2021.
  • 262 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2022.

Based on Brave Asset Management's 13F filing for Q2 2022, filed 15 Jul 2022.